{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T20:15:48Z","timestamp":1793218548662,"version":"4.5.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T00:00:00Z","timestamp":1750118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T00:00:00Z","timestamp":1750118400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100008730","name":"Kreftforeningen","doi-asserted-by":"publisher","award":["181720"],"award-info":[{"award-number":["181720"]}],"id":[{"id":"10.13039\/100008730","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008730","name":"Kreftforeningen","doi-asserted-by":"publisher","award":["5724658"],"award-info":[{"award-number":["5724658"]}],"id":[{"id":"10.13039\/100008730","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008730","name":"Kreftforeningen","doi-asserted-by":"publisher","award":["206202"],"award-info":[{"award-number":["206202"]}],"id":[{"id":"10.13039\/100008730","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","award":["21 1889 Pj"],"award-info":[{"award-number":["21 1889 Pj"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005009","name":"Stiftelsen Assar Gabrielssons Fond","doi-asserted-by":"publisher","award":["FB23-105"],"award-info":[{"award-number":["FB23-105"]}],"id":[{"id":"10.13039\/501100005009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005366","name":"University of Oslo","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005366","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-025-06644-7","type":"journal-article","created":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T15:04:59Z","timestamp":1750172699000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Beta-blockers prolong response to androgen deprivation therapy in prostate cancer through modulation of the neuro-immuno-oncology axis"],"prefix":"10.1186","volume":"23","author":[{"given":"Malin Hagberg","family":"Thulin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e5kon","family":"Ramberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi Kristin","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helene Hartvedt","family":"Grytli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivanthe","family":"Sivanesan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhilash D.","family":"Pandya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotryna","family":"Seip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kjetil Wessel","family":"Andressen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Linder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"\u00d8ijordsbakken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matti","family":"Poutanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betina","family":"Katz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bente","family":"Halvorsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunhild Mari","family":"M\u00e6landsmo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5530-4915","authenticated-orcid":false,"given":"Kristin Austlid","family":"Task\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,17]]},"reference":[{"issue":"3","key":"6644_CR1","first-page":"365","volume":"4","author":"T Chandrasekar","year":"2015","unstructured":"Chandrasekar T, Yang JC, Gao AC, Evans CP. Mechanisms of resistance in castration-resistant prostate cancer (CRPC). Transl Androl Urol. 2015;4(3):365\u201380.","journal-title":"Transl Androl Urol"},{"issue":"12","key":"6644_CR2","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1097\/COC.0000000000001134","volume":"47","author":"S Lehrer","year":"2024","unstructured":"Lehrer S, Rheinstein PH. Salbutamol, a short acting beta-2 agonist, reduces risk and improves prognosis of prostate cancer. Am J Clin Oncol. 2024;47(12):591\u20134.","journal-title":"Am J Clin Oncol"},{"key":"6644_CR3","doi-asserted-by":"publisher","first-page":"985","DOI":"10.2147\/OTT.S78836","volume":"8","author":"H Lu","year":"2015","unstructured":"Lu H, Liu X, Guo F, Tan S, Wang G, Liu H, et al. Impact of beta-blockers on prostate cancer mortality: a meta-analysis of 16,825 patients. Onco Targets Ther. 2015;8:985\u201390.","journal-title":"Onco Targets Ther"},{"issue":"7","key":"6644_CR4","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1007\/s00432-014-1658-7","volume":"140","author":"CH Choi","year":"2014","unstructured":"Choi CH, Song T, Kim TH, Choi JK, Park JY, Yoon A, et al. Meta-analysis of the effects of beta blocker on survival time in cancer patients. J Cancer Res Clin Oncol. 2014;140(7):1179\u201388.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"11","key":"6644_CR5","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1002\/bco2.441","volume":"5","author":"AH Zahalka","year":"2024","unstructured":"Zahalka AH, Fram E, Garden E, Howard L, Wiggins E, Babar M, et al. Association between beta-blocker atenolol use and prostate cancer upgrading in active surveillance. BJUI Compass. 2024;5(11):1095\u2013100.","journal-title":"BJUI Compass"},{"issue":"3","key":"6644_CR6","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1002\/pros.22564","volume":"73","author":"HH Grytli","year":"2013","unstructured":"Grytli HH, Fagerland MW, Fossa SD, Tasken KA, Haheim LL. Use of beta-blockers is associated with prostate cancer-specific survival in prostate cancer patients on androgen deprivation therapy. Prostate. 2013;73(3):250\u201360.","journal-title":"Prostate"},{"issue":"3","key":"6644_CR7","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.eururo.2013.01.007","volume":"65","author":"HH Grytli","year":"2014","unstructured":"Grytli HH, Fagerland MW, Fossa SD, Tasken KA. Association between use of beta-blockers and prostate cancer-specific survival: a cohort study of 3561 prostate cancer patients with high-risk or metastatic disease. Eur Urol. 2014;65(3):635\u201341.","journal-title":"Eur Urol"},{"issue":"1","key":"6644_CR8","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.45230","volume":"5","author":"S Sivanesan","year":"2022","unstructured":"Sivanesan S, Tasken KA, Grytli HH. Association of beta-blocker use at time of radical prostatectomy with rate of treatment for prostate cancer recurrence. JAMA Netw Open. 2022;5(1): e2145230.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"6644_CR9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pros.24623","volume":"84","author":"A Uleri","year":"2024","unstructured":"Uleri A, Baboudjian M, Tedde A, Rajwa P, Pradere B, Gallioli A, et al. The association between beta-blockers use and prostate cancer mortality: a mini systematic review and meta-analysis. Prostate. 2024;84(1):3\u20137.","journal-title":"Prostate"},{"key":"6644_CR10","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.urology.2021.02.008","volume":"155","author":"NM Posielski","year":"2021","unstructured":"Posielski NM, Richards KA, Liou JI, Borza T, Abel EJ, Downs TM, Jarrard DF. Beta-adrenergic antagonists and cancer specific survival in patients with advanced prostate cancer: a veterans administration cohort study. Urology. 2021;155:186\u201391.","journal-title":"Urology"},{"issue":"6361","key":"6644_CR11","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1126\/science.aah5072","volume":"358","author":"AH Zahalka","year":"2017","unstructured":"Zahalka AH, Arnal-Estape A, Maryanovich M, Nakahara F, Cruz CD, Finley LWS, Frenette PS. Adrenergic nerves activate an angio-metabolic switch in prostate cancer. Science. 2017;358(6361):321\u20136.","journal-title":"Science"},{"issue":"6142","key":"6644_CR12","doi-asserted-by":"publisher","first-page":"1236361","DOI":"10.1126\/science.1236361","volume":"341","author":"C Magnon","year":"2013","unstructured":"Magnon C, Hall SJ, Lin J, Xue X, Gerber L, Freedland SJ, Frenette PS. Autonomic nerve development contributes to prostate cancer progression. Science. 2013;341(6142):1236361.","journal-title":"Science"},{"issue":"15","key":"6644_CR13","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1002\/pros.23067","volume":"75","author":"S Ciftci","year":"2015","unstructured":"Ciftci S, Yilmaz H, Ciftci E, Simsek E, Ustuner M, Yavuz U, et al. Perineural invasion in prostate biopsy specimens is associated with increased bone metastasis in prostate cancer. Prostate. 2015;75(15):1783\u20139.","journal-title":"Prostate"},{"issue":"1","key":"6644_CR14","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12894-018-0319-6","volume":"18","author":"LJ Zhang","year":"2018","unstructured":"Zhang LJ, Wu B, Zha ZL, Qu W, Zhao H, Yuan J, Feng YJ. Perineural invasion as an independent predictor of biochemical recurrence in prostate cancer following radical prostatectomy or radiotherapy: a systematic review and meta-analysis. BMC Urol. 2018;18(1):5.","journal-title":"BMC Urol"},{"issue":"1","key":"6644_CR15","doi-asserted-by":"publisher","first-page":"2284486","DOI":"10.1080\/2162402X.2023.2284486","volume":"12","author":"K Carnet Le Provost","year":"2023","unstructured":"Carnet Le Provost K, Kepp O, Kroemer G, Bezu L. Trial watch: beta-blockers in cancer therapy. Oncoimmunology. 2023;12(1):2284486.","journal-title":"Oncoimmunology."},{"issue":"11","key":"6644_CR16","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1002\/pros.23994","volume":"80","author":"A Linder","year":"2020","unstructured":"Linder A, Larsson K, Welen K, Damber JE. RGS2 is prognostic for development of castration resistance and cancer-specific survival in castration-resistant prostate cancer. Prostate. 2020;80(11):799\u2013810.","journal-title":"Prostate"},{"issue":"D1","key":"6644_CR17","doi-asserted-by":"publisher","first-page":"D1438","DOI":"10.1093\/nar\/gkad944","volume":"52","author":"SD Harding","year":"2024","unstructured":"Harding SD, Armstrong JF, Faccenda E, Southan C, Alexander SPH, Davenport AP, et al. The IUPHAR\/BPS Guide to PHARMACOLOGY in 2024. Nucleic Acids Res. 2024;52(D1):D1438\u201349.","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"6644_CR18","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.3390\/nano11051140","volume":"11","author":"AD Pandya","year":"2021","unstructured":"Pandya AD, Iversen TG, Moestue S, Grinde MT, Morch Y, Snipstad S, et al. Biodistribution of Poly(alkyl cyanoacrylate) nanoparticles in mice and effect on tumor infiltration of macrophages into a patient-derived breast cancer xenograft. Nanomaterials (Basel). 2021;11(5):1140.","journal-title":"Nanomaterials (Basel)."},{"issue":"6","key":"6644_CR19","doi-asserted-by":"publisher","first-page":"588","DOI":"10.7150\/ijbs.8671","volume":"10","author":"B Kahn","year":"2014","unstructured":"Kahn B, Collazo J, Kyprianou N. Androgen receptor as a driver of therapeutic resistance in advanced prostate cancer. Int J Biol Sci. 2014;10(6):588\u201395.","journal-title":"Int J Biol Sci"},{"issue":"32","key":"6644_CR20","doi-asserted-by":"publisher","first-page":"8253","DOI":"10.1200\/JCO.2005.03.4777","volume":"23","author":"HI Scher","year":"2005","unstructured":"Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol. 2005;23(32):8253\u201361.","journal-title":"J Clin Oncol"},{"issue":"3","key":"6644_CR21","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.ccell.2023.02.012","volume":"41","author":"D Hanahan","year":"2023","unstructured":"Hanahan D, Monje M. Cancer hallmarks intersect with neuroscience in the tumor microenvironment. Cancer Cell. 2023;41(3):573\u201380.","journal-title":"Cancer Cell"},{"issue":"1","key":"6644_CR22","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ccr.2010.05.026","volume":"18","author":"BS Taylor","year":"2010","unstructured":"Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010;18(1):11\u201322.","journal-title":"Cancer Cell"},{"issue":"5","key":"6644_CR23","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.ccr.2011.04.008","volume":"19","author":"BS Carver","year":"2011","unstructured":"Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandarlapaty S, et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell. 2011;19(5):575\u201386.","journal-title":"Cancer Cell"},{"issue":"6","key":"6644_CR24","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.ccr.2011.05.006","volume":"19","author":"DJ Mulholland","year":"2011","unstructured":"Mulholland DJ, Tran LM, Li Y, Cai H, Morim A, Wang S, et al. Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. Cancer Cell. 2011;19(6):792\u2013804.","journal-title":"Cancer Cell"},{"issue":"3","key":"6644_CR25","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1158\/1078-0432.CCR-18-0981","volume":"25","author":"JS de Bono","year":"2019","unstructured":"de Bono JS, De Giorgi U, Rodrigues DN, Massard C, Bracarda S, Font A, et al. Randomized phase II study evaluating akt blockade with ipatasertib, in combination with abiraterone, in patients with metastatic prostate cancer with and without PTEN loss. Clin Cancer Res. 2019;25(3):928\u201336.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"6644_CR26","doi-asserted-by":"publisher","first-page":"3464","DOI":"10.3390\/ijms22073464","volume":"22","author":"R Mishra","year":"2021","unstructured":"Mishra R, Patel H, Alanazi S, Kilroy MK, Garrett JT. PI3K inhibitors in cancer: clinical implications and adverse effects. Int J Mol Sci. 2021;22(7):3464.","journal-title":"Int J Mol Sci"},{"issue":"20","key":"6644_CR27","doi-asserted-by":"publisher","first-page":"11088","DOI":"10.3390\/ijms222011088","volume":"22","author":"T Pungsrinont","year":"2021","unstructured":"Pungsrinont T, Kallenbach J, Baniahmad A. Role of PI3K-AKT-mTOR pathway as a pro-survival signaling and resistance-mediating mechanism to therapy of prostate cancer. Int J Mol Sci. 2021;22(20):11088.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"6644_CR28","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.3390\/cancers12061448","volume":"12","author":"S Martellucci","year":"2020","unstructured":"Martellucci S, Clementi L, Sabetta S, Mattei V, Botta L, Angelucci A. Src family kinases as therapeutic targets in advanced solid tumors: what we have learned so far. Cancers (Basel). 2020;12(6):1448.","journal-title":"Cancers (Basel)."},{"issue":"2","key":"6644_CR29","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41568-019-0216-7","volume":"20","author":"G Hoxhaj","year":"2020","unstructured":"Hoxhaj G, Manning BD. The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism. Nat Rev Cancer. 2020;20(2):74\u201388.","journal-title":"Nat Rev Cancer"},{"issue":"17","key":"6644_CR30","doi-asserted-by":"publisher","first-page":"4385","DOI":"10.1158\/0008-5472.CAN-21-1392","volume":"81","author":"LA Sena","year":"2021","unstructured":"Sena LA, Denmeade SR. Fatty acid synthesis in prostate cancer: vulnerability or epiphenomenon? Cancer Res. 2021;81(17):4385\u201393.","journal-title":"Cancer Res"},{"issue":"2","key":"6644_CR31","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.cmet.2014.06.004","volume":"20","author":"JV Lee","year":"2014","unstructured":"Lee JV, Carrer A, Shah S, Snyder NW, Wei S, Venneti S, et al. Akt-dependent metabolic reprogramming regulates tumor cell histone acetylation. Cell Metab. 2014;20(2):306\u201319.","journal-title":"Cell Metab"},{"issue":"2","key":"6644_CR32","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1073\/pnas.1808834116","volume":"116","author":"G Zadra","year":"2019","unstructured":"Zadra G, Ribeiro CF, Chetta P, Ho Y, Cacciatore S, Gao X, et al. Inhibition of de novo lipogenesis targets androgen receptor signaling in castration-resistant prostate cancer. Proc Natl Acad Sci U S A. 2019;116(2):631\u201340.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"33","key":"6644_CR33","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2220472120","volume":"120","author":"Z Wang","year":"2023","unstructured":"Wang Z, Petricca J, Liu M, Zhang S, Chen S, Li M, et al. SETD7 functions as a transcription repressor in prostate cancer via methylating FOXA1. Proc Natl Acad Sci U S A. 2023;120(33): e2220472120.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"6644_CR34","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/path.5587","volume":"253","author":"DC Bastos","year":"2021","unstructured":"Bastos DC, Ribeiro CF, Ahearn T, Nascimento J, Pakula H, Clohessy J, et al. Genetic ablation of FASN attenuates the invasive potential of prostate cancer driven by Pten loss. J Pathol. 2021;253(3):292\u2013303.","journal-title":"J Pathol"},{"issue":"28","key":"6644_CR35","doi-asserted-by":"publisher","first-page":"43713","DOI":"10.18632\/oncotarget.9666","volume":"7","author":"S Shah","year":"2016","unstructured":"Shah S, Carriveau WJ, Li J, Campbell SL, Kopinski PK, Lim HW, et al. Targeting ACLY sensitizes castration-resistant prostate cancer cells to AR antagonism by impinging on an ACLY-AMPK-AR feedback mechanism. Oncotarget. 2016;7(28):43713\u201330.","journal-title":"Oncotarget"},{"issue":"23","key":"6644_CR36","doi-asserted-by":"publisher","first-page":"5900","DOI":"10.3390\/cancers14235900","volume":"14","author":"P Makhov","year":"2022","unstructured":"Makhov P, Fazliyeva R, Tufano A, Uzzo RG, Cai KQ, Serebriiskii I, et al. Acetyl-CoA counteracts the inhibitory effect of antiandrogens on androgen receptor signaling in prostate cancer cells. Cancers (Basel). 2022;14(23):5900.","journal-title":"Cancers (Basel)."},{"issue":"5","key":"6644_CR37","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1158\/2159-8290.CD-20-0751","volume":"11","author":"J Welti","year":"2021","unstructured":"Welti J, Sharp A, Brooks N, Yuan W, McNair C, Chand SN, et al. Targeting the p300\/CBP axis in lethal prostate cancer. Cancer Discov. 2021;11(5):1118\u201337.","journal-title":"Cancer Discov"},{"issue":"16","key":"6644_CR38","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1002\/pros.24428","volume":"82","author":"MJ Filon","year":"2022","unstructured":"Filon MJ, Gillette AA, Yang B, Khemees TA, Skala MC, Jarrard DF. Prostate cancer cells demonstrate unique metabolism and substrate adaptability acutely after androgen deprivation therapy. Prostate. 2022;82(16):1547\u201357.","journal-title":"Prostate"},{"issue":"12","key":"6644_CR39","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1038\/s41556-023-01274-x","volume":"25","author":"JM Giafaglione","year":"2023","unstructured":"Giafaglione JM, Crowell PD, Delcourt AML, Hashimoto T, Ha SM, Atmakuri A, et al. Prostate lineage-specific metabolism governs luminal differentiation and response to antiandrogen treatment. Nat Cell Biol. 2023;25(12):1821\u201332.","journal-title":"Nat Cell Biol"},{"issue":"7","key":"6644_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2020.100781","volume":"13","author":"AM Decker","year":"2020","unstructured":"Decker AM, Decker JT, Jung Y, Cackowski FC, Daignault-Newton S, Morgan TM, et al. Adrenergic blockade promotes maintenance of dormancy in prostate cancer through upregulation of GAS6. Transl Oncol. 2020;13(7): 100781.","journal-title":"Transl Oncol"},{"key":"6644_CR41","doi-asserted-by":"publisher","first-page":"794","DOI":"10.3389\/fimmu.2018.00794","volume":"9","author":"MR Gubbels Bupp","year":"2018","unstructured":"Gubbels Bupp MR, Jorgensen TN. Androgen-induced immunosuppression. Front Immunol. 2018;9:794.","journal-title":"Front Immunol"},{"issue":"2\u20133","key":"6644_CR42","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s12026-014-8517-0","volume":"58","author":"FS Dhabhar","year":"2014","unstructured":"Dhabhar FS. Effects of stress on immune function: the good, the bad, and the beautiful. Immunol Res. 2014;58(2\u20133):193\u2013210.","journal-title":"Immunol Res"},{"issue":"8","key":"6644_CR43","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1007\/s00262-023-03445-z","volume":"72","author":"S Thapa","year":"2023","unstructured":"Thapa S, Cao X. Nervous regulation: beta-2-adrenergic signaling in immune homeostasis, cancer immunotherapy, and autoimmune diseases. Cancer Immunol Immunother. 2023;72(8):2549\u201356.","journal-title":"Cancer Immunol Immunother"},{"issue":"5","key":"6644_CR44","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1016\/j.ajpath.2012.07.008","volume":"181","author":"JJ Lai","year":"2012","unstructured":"Lai JJ, Lai KP, Zeng W, Chuang KH, Altuwaijri S, Chang C. Androgen receptor influences on body defense system via modulation of innate and adaptive immune systems: lessons from conditional AR knockout mice. Am J Pathol. 2012;181(5):1504\u201312.","journal-title":"Am J Pathol"},{"issue":"7915","key":"6644_CR45","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/s41586-022-04522-6","volume":"606","author":"X Guan","year":"2022","unstructured":"Guan X, Polesso F, Wang C, Sehrawat A, Hawkins RM, Murray SE, et al. Androgen receptor activity in T cells limits checkpoint blockade efficacy. Nature. 2022;606(7915):791\u20136.","journal-title":"Nature"},{"issue":"5","key":"6644_CR46","doi-asserted-by":"publisher","first-page":"295","DOI":"10.5483\/BMBRep.2015.48.5.008","volume":"48","author":"JF Qin","year":"2015","unstructured":"Qin JF, Jin FJ, Li N, Guan HT, Lan L, Ni H, Wang Y. Adrenergic receptor beta2 activation by stress promotes breast cancer progression through macrophages M2 polarization in tumor microenvironment. BMB Rep. 2015;48(5):295\u2013300.","journal-title":"BMB Rep"},{"key":"6644_CR47","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.bbi.2019.06.004","volume":"81","author":"Y Xia","year":"2019","unstructured":"Xia Y, Wei Y, Li ZY, Cai XY, Zhang LL, Dong XR, et al. Catecholamines contribute to the neovascularization of lung cancer via tumor-associated macrophages. Brain Behav Immun. 2019;81:111\u201321.","journal-title":"Brain Behav Immun"},{"issue":"3","key":"6644_CR48","doi-asserted-by":"publisher","first-page":"C554","DOI":"10.1152\/ajpcell.00016.2022","volume":"322","author":"C Xie","year":"2022","unstructured":"Xie C, Mondal DK, Ulas M, Neill T, Iozzo RV. Oncosuppressive roles of decorin through regulation of multiple receptors and diverse signaling pathways. Am J Physiol Cell Physiol. 2022;322(3):C554\u201366.","journal-title":"Am J Physiol Cell Physiol"},{"issue":"17","key":"6644_CR49","doi-asserted-by":"publisher","first-page":"7216","DOI":"10.7150\/thno.78467","volume":"12","author":"L Wang","year":"2022","unstructured":"Wang L, Wang H, Luo J, Xie T, Mor G, Liao A. Decorin promotes decidual M1-like macrophage polarization via mitochondrial dysfunction resulting in recurrent pregnancy loss. Theranostics. 2022;12(17):7216\u201336.","journal-title":"Theranostics"},{"issue":"199","key":"6644_CR50","doi-asserted-by":"publisher","first-page":"ra75","DOI":"10.1126\/scisignal.2001868","volume":"4","author":"R Merline","year":"2011","unstructured":"Merline R, Moreth K, Beckmann J, Nastase MV, Zeng-Brouwers J, Tralhao JG, et al. Signaling by the matrix proteoglycan decorin controls inflammation and cancer through PDCD4 and MicroRNA-21. Sci Signal. 2011;4(199):ra75.","journal-title":"Sci Signal."},{"issue":"1","key":"6644_CR51","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/s41598-020-79978-5","volume":"11","author":"JAF Demandt","year":"2021","unstructured":"Demandt JAF, Dubois LJ, van Kuijk K, Zatovicova M, Jin H, Parkkila S, et al. The hypoxia-sensor carbonic anhydrase IX affects macrophage metabolism, but is not a suitable biomarker for human cardiovascular disease. Sci Rep. 2021;11(1):425.","journal-title":"Sci Rep"},{"issue":"5\u20136","key":"6644_CR52","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1089\/hum.2021.050","volume":"33","author":"Y Qu","year":"2022","unstructured":"Qu Y, Dunn ZS, Chen X, MacMullan M, Cinay G, Wang HY, et al. Adenosine deaminase 1 overexpression enhances the antitumor efficacy of chimeric antigen receptor-engineered T cells. Hum Gene Ther. 2022;33(5\u20136):223\u201336.","journal-title":"Hum Gene Ther"},{"issue":"3","key":"6644_CR53","doi-asserted-by":"publisher","first-page":"418","DOI":"10.3390\/biom12030418","volume":"12","author":"G Zhulai","year":"2022","unstructured":"Zhulai G, Oleinik E, Shibaev M, Ignatev K. Adenosine-metabolizing enzymes, adenosine kinase and adenosine deaminase, in cancer. Biomolecules. 2022;12(3):418.","journal-title":"Biomolecules"},{"issue":"5","key":"6644_CR54","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1172\/JCI28508","volume":"116","author":"Y Iwakura","year":"2006","unstructured":"Iwakura Y, Ishigame H. The IL-23\/IL-17 axis in inflammation. J Clin Invest. 2006;116(5):1218\u201322.","journal-title":"J Clin Invest"},{"key":"6644_CR55","doi-asserted-by":"crossref","unstructured":"Hewitt SL, Bai A, Bailey D, Ichikawa K, Zielinski J, Karp R, et al. Durable anticancer immunity from intratumoral administration of IL-23, IL-36gamma, and OX40L mRNAs. Sci Transl Med. 2019;11(477).","DOI":"10.1126\/scitranslmed.aat9143"},{"issue":"9","key":"6644_CR56","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/nri3707","volume":"14","author":"SL Gaffen","year":"2014","unstructured":"Gaffen SL, Jain R, Garg AV, Cua DJ. The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing. Nat Rev Immunol. 2014;14(9):585\u2013600.","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"6644_CR57","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1111\/j.1600-0625.2007.00677.x","volume":"17","author":"E Goyarts","year":"2008","unstructured":"Goyarts E, Matsui M, Mammone T, Bender AM, Wagner JA, Maes D, Granstein RD. Norepinephrine modulates human dendritic cell activation by altering cytokine release. Exp Dermatol. 2008;17(3):188\u201396.","journal-title":"Exp Dermatol"},{"issue":"5","key":"6644_CR58","doi-asserted-by":"publisher","first-page":"694","DOI":"10.37349\/etat.2022.00108","volume":"3","author":"MT Palano","year":"2022","unstructured":"Palano MT, Gallazzi M, Cucchiara M, Deho F, Capogrosso P, Bruno A, Mortara L. The tumor innate immune microenvironment in prostate cancer: an overview of soluble factors and cellular effectors. Explor Target Antitumor Ther. 2022;3(5):694\u2013718.","journal-title":"Explor Target Antitumor Ther"},{"key":"6644_CR59","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.12659\/MSM.906184","volume":"24","author":"Y Liu","year":"2018","unstructured":"Liu Y, Rui XX, Shi H, Qiu YH, Peng YP. Norepinephrine inhibits Th17 cells via beta2-adrenergic receptor (beta2-AR) signaling in a mouse model of rheumatoid arthritis. Med Sci Monit. 2018;24:1196\u2013204.","journal-title":"Med Sci Monit"},{"issue":"2","key":"6644_CR60","doi-asserted-by":"publisher","first-page":"147","DOI":"10.4103\/aja202173","volume":"24","author":"Z Liu","year":"2022","unstructured":"Liu Z, Zhang JY, Yang YJ, Chang K, Wang QF, Kong YY, Dai B. High IL-23+ cells infiltration correlates with worse clinical outcomes and abiraterone effectiveness in patients with prostate cancer. Asian J Androl. 2022;24(2):147\u201353.","journal-title":"Asian J Androl"},{"issue":"7714","key":"6644_CR61","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/s41586-018-0266-0","volume":"559","author":"A Calcinotto","year":"2018","unstructured":"Calcinotto A, Spataro C, Zagato E, Di Mitri D, Gil V, Crespo M, et al. IL-23 secreted by myeloid cells drives castration-resistant prostate cancer. Nature. 2018;559(7714):363\u20139.","journal-title":"Nature"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06644-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-06644-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06644-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T16:01:54Z","timestamp":1750176114000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-025-06644-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,17]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6644"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-06644-7","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,17]]},"assertion":[{"value":"7 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The animal experiments were performed according to the regulations of the Federation of European Laboratory Animals Science Association and were approved by the National Animal Research Authority (FOTS ID 4929) in Norway or by National Animal Research Authority (Ref. 171\/214) in Sweden. The Prostate Cancer Biobank at OUS (REC 28144) provided serum samples from prostate cancer patients. Information about use of beta-blockers were obtained from the Norwegian Prescription Database (REC 17379).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All the authors approved the final version of the manuscript and agreed to its publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"672"}}